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Abstract
Background: We aimed to clarify whether soluble CD40 ligand (sCD40L) activated B cells may be loaded with
HBcAg18-27 peptide and served as antigen-producing cells (APCs) to induce HBV-specific cytolytic T lymphocytes
(CTLs).
Results: Human B cells could be cultured in the presence of sCD40L up to 54 days, and the proportion of B cells
in the S phase increased from 0% to 8.34% in the culture. The expression of CD80, CD86, major histocompatibility
complex (MHC) classes I and II molecules on the sCD40L-activated B cell was significantly increased after long-time
culture. Cytometry and fluorescence microscopy showed that more than 98% sCD40L-activated B cells were loaded
by the HBcAg peptide. Furthermore, the peptide-pulsed activated B cells could induce HBcAg18-27 specific CTLs.
Conclusions: Our results demonstrate that sCD40L-activated B cells may function as APCs and induce HBV-specific
CTLs.
Background
Efficient antigen presentation by antigen presenting cells
(APCs) is critical for inducing T-cell mediated immunity
in vivo [1,2]. Dendritic cells (DCs), activated macro-
phages, and activated B cells are all capable of present-
ing antigen peptides. DCs are considered to be highly
efficient at antigen capture, processing, and migration
[3]. Therefore, DCs have been used to generate antigen-
specific T cells for immunotherapy [4-6].
Recently, it has been demonstrated that B cells may
function as APCs [1,7] in addition to the essential role
in the humoral immune response. Banchereau et al first
reported the “CD40 system” [8], and suggested to use
CD40 ligand (CD40L) stimulated B cells as an alterna-
tive or complementary APC. The CD40L-activated B
cells may be continually expanded and the B cells signif-
icantly up-regulate the expression of major histocompat-
ibility complex (MHC) class I and class II and induce
the expression of CD80 and CD86. Antigen-specific
CD40L-activated B cells may efficiently endocytose and
present antigens, such as protein, RNA, and cDNA, to
prime primary T cells and boost robust memory T-cell
responses [9]. More importantly, activated B cells may
also prime naive T-cell responses against neoantigens ex
vivo as DCs do [9]. Thus, the activated B cells may serve
as cellular adjuvants to present antigens in vivo [10].
The mechanism of chronic hepatitis B virus (HBV)
infection remains unclear. Previous studies have sug-
gested that functional impairment of DCs may mediate
suppression of viral-specific T-cell immune response,
resulting in viral persistence in the chronic HBV infec-
tion [11-13]. As another type of important APCs, B cells
may also function as primary APC in CHB infection
[14]. However, little is known whether CD40L-activated
B cells may present HBV antigen to T cells.
In this study, we set up an effective culture method
for long-term maintenance of B cells in vitro, in which
the B cells are activated by human soluble CD40L
(sCD40L). Furthermore, we provide evidence that the
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activated B cells may serve as APCs to present core pep-
tide of HBV to cytolytic T lymphocytes (CTLs).
Results
Proliferation of B cells activated by sCD40L
As a terminal cell type, B cells in peripheral blood
mononuclear cells (PBMCs) can usually be cultured for
2-3 weeks only, which limits the application of B cells as
APCs. To prolong the culture period, we added sCD40L
into the culture of PBMCs, which resulted in the pro-
longed culture period as long as 54 days in the presence
of sCD40L. FACS analyses showed that the percentage
of B cells in the culture increased significantly over the
time, and B cells accounted for about 80% of the total
PBMCs when the cells were cultured for 54 days (Figure
1a and 1b). In contrast, the PBMCs cultured in the
absence of sCD40L contained no B cells analyzed by
cytometry 20 days after culture (Figure 1d).
Additionally, cell cycle profiles analyzed by cell cycle
distribution indicated that the G1 phase decreased from
99.87% on day 3 to 88.92% on day 45, concomitant with
an increase in cells in the S phase from 0% to 8.34%
and the G2/M phase from 0.13% to 2.74% (Figure 1c).
However, no decrease in the sub-G1 cells was detected
in the culture without sCD40L. The results demon-
strated that the B cells were able to re-enter the S phase
and proliferate in the presence of sCD40L compared
with the cells cultured in the absence of sCD40L. Total
number of B cells in the presence of sCD40L increased
from 8.84 × 105 to 8.61 × 106, while the number of B
Figure 1 Proliferation profile of sCD40L-activated B cell. (a) The percentage of B cells in the PMBCs. It was about 8.21% of total cell
population at the initiative culture. (b) The percentage of B cells increased up to 70.67% of the total cells as cultured for 48 days. (c) Cells were
stained for DNA content with PI-pretreatment and analyzed of the cell cycle by flow cytometry. The y-axis shows relative cell number and the
x-axis shows DNA content. sCD40L-stimulated B cells accumulated in the phase S. (d) B cell counts in the presence or absence of sCD40L. The
x-axis shows days of cell culture and the y-axis shows the number of the B cells. sCD40L-stimulated cells increased in number but the non-
stimulated cells decreased.
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cells in the absence of sCD40L was decreased (Figure
1d). Taken together, in accordance with the previous
reports [15], our data demonstrated that B cells may
proliferate for significantly long period of time in the
presence of sCD40L. After completion of the experi-
ments on the above donor, we repeated all the culture
process from another donor’s sample; the results were
comparable or almost same.
Increased expression of CD80, CD86, MHC classes I and II
on cell surface of sCD40L-activated B cells
Previous studies demonstrate that human B cells iso-
lated from peripheral blood may be activated and the
expression levels of CD80, CD86, MHC classes I and II
molecules on the cell surface is efficiently up-regulated
by infection with Epstein-Barr virus or co-culture with
mitogen-induced cells transfected with the human
CD40L [16,17], and the B cells may serve as APCs and
induce specific CTLs. However, the previous culture sys-
tems introduced the extraneous source germ cells or
virus and limited the further clinical application
researches. In our experiment, we cultured B cells with
recombinant human (rh) sCD40L and the cells could be
continuously expanded in long term culture. To investi-
gate whether the activated B cells may serve as APC, we
detected the expression of costimulatory molecules,
including CD80, CD86, MHC classes I and II on the cell
surface by flow cytometry. Figure 2 presents that the
levels of these molecules on the sCD40L-activated B
cells were significantly increased. In contrast, the levels
of all above cell surface molecules were very low on the
B cells before activation. Thus, the results suggest that
the B cells activated by sCD40L may have the function
of APCs.
Visualization of antigen delivery to sCD40L-activated B
cells
Since the expression levels of CD80, CD86, MHC
classes I and II molecules on the B cell surface were sig-
nificantly increased after long-time culture with
sCD40L, sCD40L-activated B cells may have the func-
tion of antigen presentation. To clarify whether this is
true or not, we cultured the cells in the presence of a
fluorochrome-labeled peptide, which was derived from
the core protein of HBV. Cytometry analysis showed
that more than 98% of sCD40L-activated B cells had the
green fluorescence (Figure 3a), indicating that there was
HBV core peptide in the cells or on the surface of the
cells and the B cells might be loaded by the HBV core
peptide. We further observed the cells under fluores-
cence microscope and found that the red fluorescence
located at B cell surface was CD19-PE and the green
fluorescence (superimposition of the green FITC fluor-
escence and the red CD19-PE becomes yellow) located
in cytoplasm was HBV core peptide. The activated B
cells showed strong fluorescence after peptide pulsing at
concentrations even lower than 25 μg/mL (Figure 3b).
All of the above results indicate that the sCD40L-acti-
vated B cells may be loaded with the HBV core peptide.
The result of the HBcAg18-27 specific CTLs
To investigate whether the sCD40L-activated B cells may
present the HBV core peptide to T cells and induce spe-
cific cytotoxic T cell responses, we co-cultured the auto-
logous T cells and sCD40L-activated B cells loaded by
HBV core peptide, and then detected the CTL responses
against peptides of HBcAg 18-27 by pentamer analysis.
FCM analyses showed that 0.248% of the T cells were
induced to be HBcAg18-27 specific CTLs, while such
CTLs were only 0.122% in the absence of activated B
cells (Figure 4). Hence, the sCD40L-activated B cells may
function as APCs and induce HBV-specific CTL.
Discussion
Recently, DC-based immunotherapy has gained a lot of
interest in clinical immunology [18]. The high efficiency
of DC vaccines has been proved in anti-tumor and anti-
virus immunological treatment. However, the DCs con-
stitute only 0.1-0.5% of human PBMC. Technical diffi-
culty and high cost to obtain sufficient number of highly
enriched mature DCs have limited the clinical applica-
tions of dendritic cell vaccine.
In this study, we used recombinant human GMP-qual-
ity trimeric soluble CD40L to activate PBMC-derived B
cells. We established and optimized the culture system
for CD40L-B cells, which allows B cell activation and
proliferation without the contamination from extraneous
source germ cells and genes. It was noted that rh
sCD40L-activated B cells could be cultured in vitro for
up to 54 days under the culture condition. At the same
time, B cells significantly up-regulated MHC class I and
class II expression and induced expression of CD80 and
CD86 after activated by rh sCD40L. Unlike some recent
studies, in which B cells were co-cultured with NIH3T3
cells or other tumor cells which steadily express CD40L
[8,19], our results demonstrated that B cells could be
activated and expanded for prolonged period of time.
While previous culture system has introduced the extra-
neous source germ cells and has limited the further clin-
ical application researches, the accomplishment of
present work may be taken as an alternative way to acti-
vate primary human B cells in vitro.
Because sufficient expression of MHC and costimula-
tory molecules is closely associated with APC function,
phenotypic analysis of the cell surface molecules is
applied as a reliable surrogate readout for APC function
of B cells [20]. Moreover, costimulatory molecules CD80
and CD86 expressed on APCs are required for the
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development of T cell responses, which play important
roles in the differentiation of Th1- or Th2-phenotypes
[21]. CD80 and CD86 expressed on the surface of anti-
gen-presenting cells interact with CD28 and cytotoxic T
lymphocyte antigen-4 expressed on activated T cells.
Interaction between CD80/86 and CD28 mediates criti-
cal T cell stimulatory signals, which may cause T cells
to stably secrete IL-2 and other cytokines, and maintain
T cell survival [22]. Our experiments demonstrate that
the rh sCD40L may activate the B cells from PBMCs,
and induce a strong up-regulation of those surface
molecules associated with antigen processing on human
B lymphocytes. Functionally, our study has moved a
step forward to demonstrate that 98% of sCD40L-acti-
vated B cells may be loaded with HBcAg18-27 peptide.
Furthermore, after co-cultured with the peptide-pulsed
CD40L-B cells, more HBcAg18-27 specific CTLs were
detected in autologous PBMCs. All of these results indi-
cate that the CD40L-B cells have the characteristics of
APCs.
The weakness of this study is that all data were just
derived from 2 healthy donor samples. However, we
performed the experiments separately, not at the same
time, i.e., we cultured the B cells from one donor and
did the relevant experiments, and then we repeated all
the experiments using another donor’s sample, the
results were comparable or almost same. Thus, we con-
sider that the long-term culture system for B cells devel-
oped in this work is reproducible and the data in the
present work are sufficient to support our conclusion.
Figure 2 Detection of the expression of CD80, CD86, and MHC I and II on sCD40L-activated human B cells as surrogates of APC.
(a) The expression of surface molecules MHC-I, MHC-II, CD80, and CD86 on B cells were examined by gating CD19 positive cells by FACS
analysis. (b) The expression of MHC-I and MHC-II on B cells was expressed as the mean fluorescence intensity. (c) The expression of CD80 and
CD86 on B cells was expressed as the percents in all B cells.
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Conclusions
In summary, the present study has established an
approach for a long term culture of human B cells from
PBMCs under the stimulation of sCD40L and the
sCD40L activated B cells may serve as APCs. Further-
more, antigen presenting activity of sCD40L-acitvated B
cells was evidenced by antigen-loading and the induc-
tion of HBcAg18-27 specific CTLs in autologous
PBMCs. Thus, CD40L-activated B cells may be used as
a potential source of APCs for adoptive immunotherapy
for chronic HBV infection.
Methods
Blood samples
Peripheral blood (30 ml) was obtained by venipuncture
from two healthy donors with HLA-A2+. The donors
gave the consent and all the experiments were approved
by the Ethics Committee of Nanjing Drum Tower Hos-
pital, Nanjing University Medical School, in accordance
with guidelines of the Nation Health and Medical
Research Council of China. PBMCs were isolated by
Ficoll-density centrifugation, rinsed twice with iscoves
modified Dulbecco medium (IMDM) (Gibco BRL, Carls-
bad, USA). Approximately 3 × 107 PBMCs were
acquired; 1.6 × 107 PBMCs were further cultured for
preparing activated B cells by sCD40L, and the surplus
cells were kept in cryopreservation fluid and frozen in
liquid nitrogen for pentamer analysis.
Activation of B cells by sCD40L
PBMCs were plated in wells of 6-well plates (8 × 106
cells in 4 ml per well) in IMDM supplemented with
10% human serum with blood type AB, rh IL-4 (2 ng/
ml) (R&D Systems, Minneapolis, USA), insulin (5 μg/
ml) (Roche, Mannheim, Germany), cyclosporin A (CsA)
(5.5 × 10-7 M) (Novartis, Basel, Switzerland), transferrin
(50 μg/ml) (Eappel, USA), and gentamicin (15 μg/ml)
(Lukang, Shandong, China). Good medical practice
(GMP)-quality trimeric rh soluble CD40L (rh sCD40L)
(R&D Systems, Minneapolis, USA) was added to a final
concentration of 2 μg/ml. The culture was maintained
by replacing half medium with the same medium, in
which CsA and sCD40L were freshly added. B cells that
were cultured in the same medium except that sCD40L
were omitted served as controls.
Cell proliferation assay
Cell proliferation was determined by analysis of cell
cycle distribution with flow cytometry using Cycle Test
Plus DNA Reagent kit (Becton Dickinson, San Jose,
USA) as previously described [23]. In brief, the cultured
cells (1 × 105) were collected and digested by trypsin,
followed by adding trypsin inhibitor and RNAase, then
mixed with propidium iodide in the dark condition at 4°
C. The cells were then subjected to run on the BD
FACSCanto flow cytometer (BD Biosciences, CA, USA).
Based on the intensity of the fluorescent light signal
emitted by the DNA-binding dye, the cell populations
were located in four distinct phases, which may be
recognized in static phase (G0/G1), DNA synthesis
phase (S), and DNA mitosis phase (M), respectively [23].
Assay for cell surface molecules
The cell surface molecules, including CD86, CD80,
MHC classes I and II, on sCD40L-activated B cells were
analyzed by flow cytometry. In brief, 1 × 106 PBMCs in
100 μl PBS were rinsed twice with PBS containing 2%
FBS and divided into 3 tubes: anti-CD19-APC, anti-
CD86-FITC, and anti-CD80-PE were added into
the first tube, anti-CD19-APC, anti-MHC-II-FITC and
Figure 3 HBV core peptide was loaded on sCD40L-activated B
cells. As negative control, auto fluorescence of CD40-B cells and
isotype control are shown. (a) To gate CD19 positive cells by FACS
analysis, the green curve was isotype control and the red curve was
B cells specific binding of HBV core peptide. The y-axis shows
relative cell number and the x-axis shows the fluorescence intensity
of the cells. (b) To observe the B cells specific binding of HBV core
peptide by fluorescence microscope, the red fluorescence located at
B cell surface was CD19-PE and the yellow fluorescence
(superimposition of the green FITC fluorescence and the red CD19-
PE becomes yellow) located in cytoplasm was HBV core protein
(FITC-FLPSDFFPSV).
Figure 4 Pentamer analysis of induction of CTL responses
against peptides of HBcAg 18-27 by CD40-B cells. (a) 0.248% of
the T cells were induced to be HBcAg18-27 specific CTLs. (b) While
such CTLs were only 0.122% in the absence of activated B cells.
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anti-MHC-I-PE were added into the second tube, and in
the third tube, negative isotype control staining reac-
tions were in parallel performed with a saturating con-
centration of irrelevant mouse IgG1-FITC and IgG1-PE.
All above seven antibodies were purchased from BD
Biosciences (BD PharMingen, San Diego, CA). After
incubated for 20 min and rinsed with PBS, the cells
were fixed with 1% paraformaldehyde in PBS. FACS
analysis was performed on the BD FACSCanto flow cyt-
ometer. B cells were gated on CD19-positive cells for
analyzing the cell surface molecules.
Analysis of peptide pulsing
HBV derived peptides were used for peptide pulsing
study as previously described [24,25] with modifications.
The HLA-A*0201-binding peptide of HBV core 18-27
(HBcAg 18-27, Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-
Val, FLPSDFFPSV), a confirmed HLA-A 2.1-restricted
CTL epitope and derived from the HBV core protein
[26], was obtained from Sangon (Shanghai, China). For
the MHC class I experiments, the peptide was conju-
gated by FITC at the first residue of the N-terminus.
CD40L-activated B cells were harvested from culture,
washed 3 times, and resuspended in serum-free IMDM
at 2 × 105 cells/ml and seeded into 24-well plates (1 ml/
well). After incubation with the FITC-conjugated pep-
tide for 12-18 hours, the cells were harvested, washed,
and resuspended in PBS. Fluorescence analysis was per-
formed immediately on the BD FACSCanto flow cyt-
ometer for detecting the ratio of B cells specific binding
of HBV core peptide. The residual cells were observed
by fluorescence microscope (Zeiss, Goettingen, Ger-
many) for determining the location of HBV core peptide
in B cells. B cells were also incubated with no FITC-
conjugated peptide under the same condition for penta-
mer analysis.
Pentamer analysis
On day 45 of B cells culture from one donor, the
CD40L-activated B cells were used as the source of
APCs for stimulation of autologous T cells. In brief, the
frozen PBMCs were rapidly thawed in a 37°C water bath
and then cultured at a concentration of 2 × 106 cells/ml
in RPMI 1640 supplemented with 10% fetal bovine
serum and rhIL-2 (10 ng/ml) (R&D Systems). On day 4,
the cultures were replaced with the same medium, fol-
lowed by co-culture with the peptide-pulsed CD40L-
activated B cells. After 4 days, the cells were harvested,
washed, and mixed with both anti-CD8-FITC and PE-
labeled HLA-A2 pentamer complexes against the HBV
core 18-27 peptide (ProImmune, Oxford, UK). The cells
were resuspended in 500 μl of PBS and two-colour ana-
lysis was performed by BD FACSCanto flow cytometer.
For each analysis, 100 000 events were acquired. PBMCs
that were cultured in the same medium omitted pep-
tide-pulsed CD40-B served as controls.
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